ANI Pharmaceuticals, Inc. (BST:BSFA)
Germany · Delayed Price · Currency is EUR 77.50
-3.00 (-3.73%)
At close: Nov 6, 2025
ANI Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 826.88 | 614.38 | 486.82 | 316.39 | 216.14 | 208.48 | Upgrade | |
Revenue Growth (YoY) | 48.86% | 26.20% | 53.87% | 46.38% | 3.67% | 0.93% | Upgrade |
Cost of Revenue | 324.55 | 250.21 | 181.51 | 138.79 | 100.61 | 87.16 | Upgrade |
Gross Profit | 502.34 | 364.17 | 305.3 | 177.6 | 115.53 | 121.32 | Upgrade |
Selling, General & Admin | 303.87 | 237.24 | 161.7 | 124.04 | 84.29 | 64.99 | Upgrade |
Research & Development | 56.05 | 44.58 | 34.29 | 22.32 | 11.37 | 16 | Upgrade |
Other Operating Expenses | -2.66 | - | - | - | 0.78 | 11.26 | Upgrade |
Operating Expenses | 448.67 | 349.55 | 255.77 | 203.33 | 143.7 | 136.89 | Upgrade |
Operating Income | 53.66 | 14.62 | 49.53 | -25.73 | -28.17 | -15.57 | Upgrade |
Interest Expense | -33.05 | -33.14 | -35.05 | -28.42 | -11.95 | -9.48 | Upgrade |
Interest & Investment Income | 11.38 | 15.53 | 8.11 | 0.37 | 0.02 | 0.03 | Upgrade |
Other Non Operating Income (Expenses) | -4.03 | -4.03 | -0.16 | 0.67 | -4.71 | -0.49 | Upgrade |
EBT Excluding Unusual Items | 29.05 | -7.02 | 22.43 | -53.12 | -44.8 | -25.52 | Upgrade |
Merger & Restructuring Charges | 2.42 | -12.4 | -1.13 | -5.68 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | 0.56 | 6.31 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -0.3 | 5.35 | - | - | 1.82 | - | Upgrade |
Asset Writedown | -8.37 | -7.6 | - | -0.11 | -2.37 | -0.45 | Upgrade |
Legal Settlements | - | - | - | - | -8.75 | - | Upgrade |
Other Unusual Items | 27.18 | -6.85 | -1.43 | -3.76 | -1.96 | - | Upgrade |
Pretax Income | 50.55 | -22.21 | 19.87 | -62.67 | -56.06 | -25.96 | Upgrade |
Income Tax Expense | 9.98 | -3.69 | 1.09 | -14.77 | -13.46 | -3.41 | Upgrade |
Net Income | 40.57 | -18.52 | 18.78 | -47.9 | -42.6 | -22.55 | Upgrade |
Preferred Dividends & Other Adjustments | 6.42 | 1.63 | 3.3 | 1.63 | 0.19 | - | Upgrade |
Net Income to Common | 34.15 | -20.15 | 15.48 | -49.52 | -42.79 | -22.55 | Upgrade |
Shares Outstanding (Basic) | 20 | 19 | 18 | 16 | 13 | 12 | Upgrade |
Shares Outstanding (Diluted) | 21 | 19 | 18 | 16 | 13 | 12 | Upgrade |
Shares Change (YoY) | 6.95% | 6.18% | 11.89% | 29.09% | 5.28% | -0.63% | Upgrade |
EPS (Basic) | 1.73 | -1.04 | 0.86 | -3.05 | -3.40 | -1.88 | Upgrade |
EPS (Diluted) | 1.67 | -1.04 | 0.85 | -3.05 | -3.40 | -1.88 | Upgrade |
Free Cash Flow | 155.73 | 47.78 | 110.09 | -40.08 | 0.77 | 9.13 | Upgrade |
Free Cash Flow Per Share | 7.58 | 2.47 | 6.05 | -2.46 | 0.06 | 0.76 | Upgrade |
Gross Margin | 60.75% | 59.27% | 62.71% | 56.13% | 53.45% | 58.19% | Upgrade |
Operating Margin | 6.49% | 2.38% | 10.17% | -8.13% | -13.03% | -7.47% | Upgrade |
Profit Margin | 4.13% | -3.28% | 3.18% | -15.65% | -19.80% | -10.82% | Upgrade |
Free Cash Flow Margin | 18.83% | 7.78% | 22.61% | -12.67% | 0.35% | 4.38% | Upgrade |
EBITDA | 145.07 | 82.35 | 109.32 | 33.92 | 19.08 | 29.07 | Upgrade |
EBITDA Margin | 17.54% | 13.40% | 22.46% | 10.72% | 8.83% | 13.94% | Upgrade |
D&A For EBITDA | 91.4 | 67.73 | 59.79 | 59.65 | 47.25 | 44.64 | Upgrade |
EBIT | 53.66 | 14.62 | 49.53 | -25.73 | -28.17 | -15.57 | Upgrade |
EBIT Margin | 6.49% | 2.38% | 10.17% | -8.13% | -13.03% | -7.47% | Upgrade |
Effective Tax Rate | 19.74% | - | 5.50% | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.